Although the probability of occurrence is low, studies have shown a significantly increased risk of serious adverse effects of EPO, including death, intracerebral hemorrhage, brain edema, and thromboembolic events, with high doses and co-administration of tPA [36, 37]. This evidence concerns the gene EPO and intracerebral hemorrhage.